External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>Summit updated data from the global HARMONi trial, evaluating AK112 + chemo vs chemo alone in 2L 3rd-gen EGFR-TKI resistant NSCLC.</li><li>PFS HR in the Western cohort was less favorable compared to Chinese patients, and Western OS HR at extended follow-up similarly trailed the Chinese subgroup.</li><li>Investors are concerned about the translatability of AK112’s China data to the global market.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Summit updated data from the global HARMONi trial, evaluating AK112 + chemo vs chemo alone in 2L 3rd-gen EGFR-TKI resistant NSCLC.PFS HR in the Western cohort was less favorable compared to Chinese patients, and Western OS HR at extended follow-up similarly trailed the Chinese subgroup.Investors are concerned about the translatability of AK112’s China data to the global market.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akeso (9926 HK) - OS Data Improved with Longer Follow-Up

<ul><li>In 1H25, Akeso reported product sales of RMB1.4bn (+49% YoY), achieving 43% of our prior full-year estimate, largely in line with our expectations.</li><li>The NRDL inclusions of 2L+ cervical cancer for AK104 and 2L+ EGFRm NSCLC for AK112 have contributed to the sales growth.</li><li>Looking ahead to 2026, we anticipate additional NRDL inclusions for AK104 in 1L gastric cancer and 1L cervical cancer, and for AK112 in 1L PD-L1+ NSCLC, which should further accelerate product sales growth. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

In 1H25, Akeso reported product sales of RMB1.4bn (+49% YoY), achieving 43% of our prior full-year estimate, largely in line with our expectations.The NRDL inclusions of 2L+ cervical cancer for AK104 and 2L+ EGFRm NSCLC for AK112 have contributed to the sales growth.Looking ahead to 2026, we anticipate additional NRDL inclusions for AK104 in 1L gastric cancer and 1L cervical cancer, and for AK112 in 1L PD-L1+ NSCLC, which should further accelerate product sales growth. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akeso (9926 HK) - Key Data Readouts for AK112 to Validate Global Potential

<ul><li>Ivonescimab (AK112) has demonstrated an OS benefit trend over pembrolizumab in monotherapy. In the head-to-head Ph3 HARMONi-2 study comparing Ivonescimab to pembrolizumab (Keytruda), Ivonescimab showed a notable efficacy advantage and was recently approved in China for first-line treatment of PD-L1 positive (TPS ≥1%) NSCLC.</li><li>In the interim OS analysis conducted at 39% maturity, Ivonescimab achieved a hazard ratio (HR) of 0.777 versus pembrolizumab, reducing the risk of death by 22.3%.</li><li>Although the interim analysis may not have reached statistical significance partly due to the very small alpha spending (0.0001), it suggests a favorable OS trend.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Ivonescimab (AK112) has demonstrated an OS benefit trend over pembrolizumab in monotherapy. In the head-to-head Ph3 HARMONi-2 study comparing Ivonescimab to pembrolizumab (Keytruda), Ivonescimab showed a notable efficacy advantage and was recently approved in China for first-line treatment of PD-L1 positive (TPS ≥1%) NSCLC.In the interim OS analysis conducted at 39% maturity, Ivonescimab achieved a hazard ratio (HR) of 0.777 versus pembrolizumab, reducing the risk of death by 22.3%.Although the interim analysis may not have reached statistical significance partly due to the very small alpha spending (0.0001), it suggests a favorable OS trend.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akeso (9926 HK) - Continued Optimism on the Global Potential of Ivonescimab

<ul><li>NRDL inclusion to fuel FY25 growth. Akeso’s FY24 results reflected strong cost controls despite a revenue shortfall. </li><li>The Company reported total revenue of RMB2.1bn, including RMB2.0bn from product sales, representing a 25% YoY increase.</li><li>Operating efficiency continued to improve, with SG&amp;A-toproduct sales ratio reduced to 61% from 69% in FY23 and R&amp;D expenses down 5% YoY to RMB1.2bn. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

NRDL inclusion to fuel FY25 growth. Akeso’s FY24 results reflected strong cost controls despite a revenue shortfall. The Company reported total revenue of RMB2.1bn, including RMB2.0bn from product sales, representing a 25% YoY increase.Operating efficiency continued to improve, with SG&amp;A-toproduct sales ratio reduced to 61% from 69% in FY23 and R&amp;D expenses down 5% YoY to RMB1.2bn. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akeso (9926 HK) - AK112 to Validate Its Potential as Next-Generation IO Therapy

<ul><li>In 1H24, Akeso recorded RMB1.03bn in revenue, including RMB939mn from product sales.</li><li>Cadonilimab/AK104 (PD-1/CTLA-4) recorded RMB706mn in sales in 1H24, +16% YoY or -6% HoH, accounting for 39% of our previous full-year estimate.</li><li>We attribute the weaker-than-expected sales performance to the preparation for NRDL inclusion. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

In 1H24, Akeso recorded RMB1.03bn in revenue, including RMB939mn from product sales.Cadonilimab/AK104 (PD-1/CTLA-4) recorded RMB706mn in sales in 1H24, +16% YoY or -6% HoH, accounting for 39% of our previous full-year estimate.We attribute the weaker-than-expected sales performance to the preparation for NRDL inclusion. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akeso (9926 HK) - Eyes on the Detailed Head-To-Head Data of AK112 at WCLC in Sep

China

Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Akeso Biopharma Inc (9926 HK)

Akeso (9926 HK) - OS Data Improved with Longer Follow-Up

Summit updated data from the global HARMONi trial, evaluating AK112 + chemo vs chemo alone in 2L 3rd-gen EGFR-TKI resistant NSCLC.

CMB International

Akeso (9926 HK) - Key Data Readouts for AK112 to Validate Global Potential

In 1H25, Akeso reported product sales of RMB1.4bn (+49% YoY), achieving 43% of our prior full-year estimate, largely in line with our expectations.

CMB International

Akeso (9926 HK) - Continued Optimism on the Global Potential of Ivonescimab

In the interim OS analysis conducted at 39% maturity, Ivonescimab achieved a hazard ratio (HR) of 0.777 versus pembrolizumab, reducing the risk of...

CMB International

Akeso (9926 HK) - AK112 to Validate Its Potential as Next-Generation IO Therapy

NRDL inclusion to fuel FY25 growth. Akeso’s FY24 results reflected strong cost controls despite a revenue shortfall. The Company reported total...

CMB International

Akeso (9926 HK) - Eyes on the Detailed Head-To-Head Data of AK112 at WCLC in Sep

Akeso recorded RMB239mn of attributable net loss in 1H24. As of Jun 2024, Akeso had a sufficient cash balance of RMB5.69bn.

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)